Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer

Abstract Mutant KRAS is a key driver in colorectal cancer (CRC) and promotes Myc translation and Myc-dependent stress adaptation and proliferation. Here, we report that the combination of two FDA-approved drugs Bortezomib and Everolimus (RAD001) (BR) is highly efficacious against mutant KRAS CRC cel...

Полное описание

Библиографические подробности

Главные авторы:	Hang Ruan, Brian J. Leibowitz, Yingpeng Peng, Lin Shen, Lujia Chen, Charlie Kuang, Robert E. Schoen, Xinghua Lu, Lin Zhang, Jian Yu
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Springer 2022-03-01
Серии:	Molecular Biomedicine
Предметы:	Mutant KRAS Myc eIF2α Colorectal cancer Everolimus Bortezomib
Online-ссылка:	https://doi.org/10.1186/s43556-022-00070-7
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!